~~<i id='3772F976A7'><strike id='3772F976A7'><tt id='3772F976A7'><pre id='3772F976A7'></pre></tt></strike></i>~~

Home» leisure time» knowledge

knowledge

author：leisure time 2025-09-30 22:40:16 Page View：6

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Doulas covered by Medicaid under New York's new plan
Next article： Alkermes shareholders re

explore

Medicare proposal to cover medical devices draws a mixed reaction

AdobeThemedicaldeviceindustryissplitonwhetheraproposednewMedicarereimbursementpathwaywilldoanythingt

ActiGraph execs on goal of drug approvals with digital endpoints

JeremeyWyattActiGraphAsdrugmakerswadeintousingdigitalhealthtechnologies,ActiGraphhasmadeitsmissionto

State Dept. review finds Biden bears some blame for Afghanistan failures

3:53HundredsofpeoplegathernearaU.S.AirForceC-17transportplaneattheperimeteroftheinternationalairport

Eye stem cell transplant could help restore vision in injured people

UlaJurkunas,associatedirectorofthecorneaserviceatMassEyeandEar,performsthefirstCALECsurgery.Courtesy